• In Vitro Susceptibility of Canine Staphylococci to Novobioci

  2026-07-25

  This study systematically evaluates the in vitro activity of novobiocin and mupirocin against methicillin-susceptible and methicillin-resistant staphylococci isolated from healthy dogs and dogs with superficial pyoderma. The findings refine antimicrobial selection for veterinary dermatology and inform future antibacterial resistance research.

• Recombinant Mouse Sonic Hedgehog: Experimental Workflows & I

  2026-07-24

  Recombinant Mouse Sonic Hedgehog (SHH) protein enables precise modeling of morphogen-driven development and congenital malformation in vitro. This guide translates new comparative findings into actionable protocols, troubleshooting, and workflow enhancements for hedgehog signaling pathway research.

• Lysoptosis: Conserved Cell Death Via Cathepsin Activity Mode

  2026-07-24

  The reference study identifies lysoptosis as a distinct, evolutionarily conserved lysosome-dependent cell death pathway, regulated by intracellular serpins. This discovery clarifies the mechanistic role of cathepsin release and cysteine protease activity in cellular demise, opening avenues for precise investigation into regulated cell death in both model organisms and mammalian systems.

• GPNMB-Based Model Predicts Immunotherapy Response in ESCC

  2026-07-23

  This study introduces a multimodal predictive model integrating circulating GPNMB, CAF-epithelial niche features, and clinical data to forecast immunotherapy response in esophageal squamous cell carcinoma (ESCC). The research elucidates how tumor-derived soluble GPNMB contributes to CD8+ T cell exhaustion and resistance to PD-1 blockade, informing precision patient stratification strategies.

• Ziprasidone HCl: Protocols and Innovations in Translational

  2026-07-23

  Ziprasidone HCl stands out as a dual-action tool for neuroscience and oncology research, enabling precise control of dopaminergic and serotonergic pathways and targeting tumor metabolism. This article decodes advanced workflows, highlights a breakthrough formulation method for enhanced bioavailability, and delivers actionable troubleshooting insights for bench scientists.

• MLN8237 (Alisertib): Mechanistic Leverage for Translational

  2026-07-22

  This thought-leadership article provides a strategic, evidence-based exploration of MLN8237 (Alisertib) as a selective Aurora A kinase inhibitor, integrating deep mechanistic insight with actionable guidance for translational researchers. Drawing on recent molecular mechanistic assays and advanced workflow experiences, it outlines a modern roadmap for leveraging MLN8237 in cancer biology, apoptosis induction, and tumor suppression, while contextualizing its competitive advantages and real-world translational relevance.

• Reliable Gene Expression Analysis with HyperScript RT SuperM

  2026-07-22

  This scenario-driven article explores real laboratory challenges in cell viability and gene expression analysis, demonstrating how HyperScript™ RT SuperMix for qPCR (SKU K1074) ensures reproducible, high-sensitivity cDNA synthesis from complex or low-abundance RNA. Drawing on evidence-based best practices and the latest research, we guide biomedical scientists in optimizing qRT-PCR workflows using APExBIO's validated reagent.

• Enhancing Reporter Assays with EZ Cap™ mCherry mRNA (5mCTP,

  2026-07-21

  This article addresses practical hurdles in cell-based viability and proliferation assays, highlighting how EZ Cap™ mCherry mRNA (5mCTP, ψUTP) (SKU R1017) delivers reproducible, immune-silent red fluorescent protein expression. Backed by evidence and real-world protocols, it guides biomedical researchers on optimizing reporter gene mRNA workflows for sensitivity, stability, and data reliability.

• Mechanistic Insights into Diuron-Induced Acute Renal Injury

  2026-07-21

  This study integrates network toxicology, molecular docking, and experimental validation to reveal how Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea) induces acute kidney injury via the JAK2/STAT1 pathway. These findings advance mechanistic understanding of Diuron's nephrotoxicity, highlighting implications for environmental toxicology and risk assessment.

• Arctigenin Mitigates Doxorubicin Cardiotoxicity via KEAP1-NR

  2026-07-20

  This study identifies arctigenin, discovered through high-throughput screening, as a natural inhibitor of the KEAP1-NRF2 interaction that protects against doxorubicin-induced cardiotoxicity. The findings illuminate a novel mechanism for cardioprotection and suggest new strategies for reducing the side effects of anthracycline chemotherapy.

• Recombinant Human Growth Hormone: Applied Workflows & Troubl

  2026-07-20

  Unlock reproducible, high-impact growth hormone research with validated workflows leveraging Recombinant Human Growth Hormone (GH). This guide details protocol setup, advanced applications, and troubleshooting strategies, all grounded in the latest mechanistic findings and product performance data.

• Redox-Active Vitamin C Induces Non-Apoptotic Death in Osteos

  2026-07-19

  This study demonstrates that pharmacological, oxidizable vitamin C selectively suppresses human osteosarcoma growth by triggering a cascade of intracellular ROS-iron–calcium signaling and mitochondrial dysfunction. The findings clarify the distinct, non-apoptotic cell death mechanisms induced by high-dose vitamin C, suggesting new avenues for metabolic targeting in cancer research.

• Methylprednisolone Sodium Succinate in Inflammation Research

  2026-07-18

  Methylprednisolone Sodium Succinate enables precise modulation of inflammation and immune signaling in both cellular and translational models. This article details evidence-led workflows, protocol parameters, and troubleshooting strategies for maximizing reproducibility and insight in experimental immunology. Explore how this synthetic corticosteroid can advance acute injury and apoptosis research.

• Targeting CREBBP/EP300: New Strategies for LUAD Epigenetics

  2026-07-17

  This thought-leadership article explores the emerging role of CREBBP/EP300 bromodomain inhibition in dissecting super-enhancer-driven transcriptional programs within early-stage lung adenocarcinoma (LUAD). Drawing on recent mechanistic insights—including the pivotal role of LINC01977 super-enhancer hijacking and TGF-β/SMAD3 signaling—the piece guides translational researchers through the rationale for targeting epigenetic coactivators, highlights SGC-CBP30 as a precision research tool, and outlines actionable protocols and future directions for cancer biology and epigenetics research.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Empowering EMT and

  2026-07-17

  Discover how the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody advances immunofluorescence and cell polarity studies in ovarian cancer EMT. This in-depth guide explores its unique amplification capabilities and links scientific findings to practical assay design.

464 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page